1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?

The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in part by a handful of products (Avonex, Betaseron, Copaxone and Rebif) that are both effective, very well established and which deliver broadly comparable efficacy. In more recent years, an 'oral revolution' has advanced the therapeutic optionality for MS patients, but simultaneously left room for further improvements.

As patients await the next generation of therapies to emerge from the clinic – potentially improving care in certain subtypes of the disease or facilitating the repair of damage caused by MS – another dynamic is likely to emerge via the potential launch of generic Copaxone products.

Despite the competitive nature of this disease market, prices for MS drugs have risen notably in recent years; a recently published (by Bloomberg) list of 73 drugs that have seen a US list price increase of 75 percent or more since 2007 included five of the most widely prescribed MS drugs.

With the potential launch of generic Copaxone set to provide some form of platform for pricing pressure, will other factors that have driven brand loyalty in MS be overlooked or will the dynamics that have allowed this therapy to persist as one the strongest growing in recent years remain in place?

Against this backdrop, FirstWord polled 186 neurologists based in the US and EU5 to ask them a series of questions about their approach to using MS therapies. Specifically we asked them...

- How they rate their personal level of loyalty to the MS treatments they prescribe?
- In what segment of the MS market is their loyalty to particular products strongest?
- What a new therapy would need to demonstrate versus existing treatments to change their prescribing habits?
- What clinical attribute (apart from efficacy) they believe is the most important differentiator between approved MS therapies?
- What commercial attribute they believe is the most important differentiator between approved MS therapies?

Table Of Contents

Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19 Summary Cancer vaccines are being ...

Global Cancer Monoclonal Antibodies Market

Global Cancer Monoclonal Antibodies Market

  • $ 4250
  • Industry report
  • December 2016
  • by Mordor Intelligence LLP

The global cancer monoclonal antibodies market was valued at USD 27 billion for the year 2015 and is expected to grow at a CAGR of around 8-15% from 2016 to 2021. The interaction between a person’s genetic ...

Protein Therapeutics Market Analysis and Trends- Therapeutic Proteins (Bone morphogenetic proteins, Interferon (IFN), Insulin and Engineered protein scaffolds), Application (Cancer and Fertility), Function  - Forecast to 2025

Protein Therapeutics Market Analysis and Trends- Therapeutic Proteins (Bone morphogenetic proteins, Interferon (IFN), Insulin and Engineered protein scaffolds), Application (Cancer and Fertility), Function - Forecast to 2025

  • $ 4200
  • Industry report
  • November 2016
  • by Accuray Research LLP

The Global Protein Therapeutics Devices Market is poised to grow at a CAGR of around 8.6% over the next decade to reach approximately $315.90 billion by 2025. Some of the prominent trends that the market ...


Download Unlimited Documents from Trusted Public Sources

Influenza Statistics in India

  • January 2017
    6 pages
  • Influenza  

    Vaccine  

    Diabetes  

  • India  

    United States  

View report >

Biosimilar Price Trends in Canada - Forecast

  • January 2017
    4 pages
  • Biosimilar  

  • Canada  

    North America  

View report >

Biotech Statistics in Europe

  • January 2017
    20 pages
  • Biotech  

    Biopharmaceutic...  

  • Europe  

    World  

View report >

Related Market Segments :

Therapy

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.